Claims for Patent: 9,422,574

Summary for Patent: 9,422,574

Title:	Mammalian expression vector
Abstract:	The invention provides vector nucleic acid for expressing at least one polypeptide of interest in a mammalian cell, comprising (a) at least one expression cassette (POI) for expressing a polypeptide of interest; (b) an expression cassette (MSM) comprising a mammalian selectable marker gene; (c) an expression cassette (MASM) comprising a mammalian amplifiable, selectable marker gene; wherein the expression cassette (POI) is flanked 5\' by the expression cassette (MASM), the expression cassette (MSM) is located 3\' from the expression cassette (POI) and wherein the expression cassettes (MASM), (POI) and (MSM) are arranged in the same 5\' to 3\' orientation. Also provided are host cells, comprising said vector and methods for producing a polypeptide using respective host cells.
Inventor(s):	Knopf; Hans-Peter (Schallstadt, DE), Wilms; Burkhard (Grenzach Wyhlen, DE)
Assignee:	Novartis AG (Basel, CH)
Application Number:	13/482,117
Patent Claims:	1. A vector nucleic acid suitable for expressing at least one polypeptide of interest in a mammalian cell, comprising (a) at least one expression cassette (POI) suitable for expressing a polypeptide of interest; (b) an expression cassette (MSM) comprising a mammalian selectable marker gene wherein said mammalian selectable marker gene is an antibiotic resistance gene; and (c) an expression cassette (MASM) comprising a mammalian amplifiable, selectable marker gene; wherein each said expression cassette (POI), (MSM), and (MASM) comprises at least one promoter or promoter/enhancer element, the expression cassette (POI) is flanked 5' by the expression cassette (MASM), the expression cassette (MSM) is located 3' from the expression cassette (POI) and the expression cassettes (MASM), (POI), and (MSM) are arranged in the same 5' to 3' orientation and wherein the vector is circular and the expression cassette (MASM) is arranged 3' of the expression cassette (MSM) and wherein said circular vector comprises a unique linearization restriction site for linearizing the vector which is located between the expression cassettes (MSM) and (MASM); or wherein the vector is linearized via a unique linearization restriction site located between the expression cassettes (MSM) and (MASM); and wherein the vector is selected from the group consisting of (a) a circular or linear vector nucleic acid comprising the following genetic elements in the indicated arrangement, wherein the 5' to 3' direction is indicated by the .fwdarw.: I) Promoter of the (MASM) expression cassette (.fwdarw.) II) Gene encoding the mammalian amplifiable selectable marker of the (MASM) expression cassette (.fwdarw.) III) Intron of the (MASM) expression cassette (.fwdarw.) IV) PolyA site of the (MASM) expression cassette (.fwdarw.) V) Promoter of the (POI) expression cassette (.fwdarw.) VI) Intron of the (POI) expression cassette (.fwdarw.) VII) Polynucleotide encoding a polypeptide of interest, which is inserted in the (POI) expression cassette (.fwdarw.) VIII) PolyA site of the (POI) expression cassette (.fwdarw.) IX) Promoter of the (POI') expression cassette (.fwdarw.) X) Intron of the (POI') expression cassette (.fwdarw.) XI) Polynucleotide encoding an additional polypeptide of interest, which is inserted in the (POI') expression cassette (.fwdarw.) XII) PolyA site of the (POI') expression cassette (.fwdarw.) XIII) Promoter of the (MSM) expression cassette (.fwdarw.) XIV) Gene encoding the mammalian selectable marker of the (MSM) expression cassette (.fwdarw.) XV) PolyA site of the (MSM) expression cassette (.fwdarw.) XVI) PSM expression cassette (.fwdarw.)or (.rarw.) XVII) Linearization restriction site if the vector nucleic acid is circular; and (b) a vector nucleic acid as shown as Seq. ID No. 1 or Seq. ID No. 16.

Details for Patent 9,422,574

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2027-12-21
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2027-12-21
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2027-12-21